Volume | 345,051 |
|
|||||
News | - | ||||||
Day High | 7.71 | Low High |
|||||
Day Low | 7.32 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Voyager Therapeutics Inc | VYGR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
7.40 | 7.32 | 7.71 | 7.62 | 7.42 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
4,463 | 345,051 | $ 7.57 | $ 2,612,060 | - | 6.06 - 14.3398 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:20:00 | formt | 306 | $ 7.62 | USD |
Voyager Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
412.68M | 54.30M | - | 250.01M | 132.33M | 2.44 | 3.12 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Voyager Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VYGR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 7.50 | 7.78 | 7.26 | 7.53 | 409,587 | 0.12 | 1.60% |
1 Month | 9.56 | 10.66 | 7.26 | 8.70 | 575,436 | -1.94 | -20.29% |
3 Months | 7.40 | 10.66 | 7.08 | 8.87 | 666,560 | 0.22 | 2.97% |
6 Months | 6.76 | 11.72 | 6.06 | 8.72 | 643,877 | 0.86 | 12.72% |
1 Year | 7.43 | 14.3398 | 6.06 | 9.47 | 556,513 | 0.19 | 2.56% |
3 Years | 5.265 | 14.3398 | 2.46 | 5.75 | 892,194 | 2.36 | 44.73% |
5 Years | 21.13 | 28.79 | 2.46 | 7.36 | 683,225 | -13.51 | -63.94% |
Voyager Therapeutics Description
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies. |